Vedolizumab, marketed as Entyvio by Takeda, is the drug quietly reshaping the treatment landscape for children and adolescents with inflammatory bowel disease. In February 2026, results from the Phase 3 KEPLER trial showed that 47.3 percent of pediatric patients with moderately to severely active ulcerative colitis achieved clinical remission at one year — a striking outcome given that every participant in the trial had already failed conventional therapies like steroids, immunomodulators, or TNF antagonists. What makes vedolizumab particularly compelling for young patients is its gut-selective mechanism: unlike older biologics that suppress the immune system broadly, this drug targets inflammation in the gastrointestinal tract without leaving growing children vulnerable to the systemic infections and complications that come with widespread immunosuppression. This matters more than the clinical numbers might suggest at first glance.
Over 100,000 American youth under age 20 are now living with IBD, according to a CDC-funded study published in Gastroenterology in November 2024. Pediatric IBD prevalence surged 133 percent between 2007 and 2016, and these children have historically been stuck waiting years for drugs that adults already have access to. A child diagnosed with Crohn’s disease or ulcerative colitis at age eight might spend a decade on therapies that were never formally tested or approved for someone their age. This article examines how vedolizumab works, what the KEPLER trial actually demonstrated, why its gut-selective approach is especially important for pediatric patients, what other drugs are in the pipeline, and what families and clinicians should understand about where pediatric IBD treatment is headed. For readers of this site who follow brain health and dementia research, the connections between chronic childhood inflammation, long-term immune modulation, and neurological outcomes deserve attention as well.
Table of Contents
- Why Is Vedolizumab Being Called a Revolution in Pediatric Inflammatory Bowel Disease?
- What the KEPLER Trial Results Actually Show — And Where They Fall Short
- The Gut-Brain Connection — Why Dementia Researchers Should Pay Attention to Pediatric IBD
- How Vedolizumab Compares to Other Biologics in the Pediatric Pipeline
- The Approval Gap — Why Pediatric Patients Wait Years for Drugs Adults Already Have
- The Rising Prevalence Problem — Why More Children Are Getting IBD
- What Comes Next for Pediatric IBD Treatment
- Conclusion
- Frequently Asked Questions
Why Is Vedolizumab Being Called a Revolution in Pediatric Inflammatory Bowel Disease?
The word “revolution” gets thrown around loosely in medicine, but the case for vedolizumab in pediatric IBD rests on a genuine structural problem. FDA-approved since May 2014 for adults with moderately to severely active ulcerative colitis and Crohn’s disease, vedolizumab has been used off-label in children for years. Pediatric gastroenterologists have prescribed it based on adult data and their own clinical judgment, but without the rigorous Phase 3 evidence that regulators require. The KEPLER trial changes that equation entirely. It was a global, randomized, double-blind, multi-center study enrolling patients ages two to seventeen — the kind of gold-standard evidence that has been conspicuously absent for most pediatric IBD treatments. To understand why this is such a departure, consider the current reality. When a twelve-year-old is diagnosed with severe ulcerative colitis, the typical escalation path moves from aminosalicylates to corticosteroids to immunomodulators like azathioprine, and then to biologic therapy — usually infliximab or adalimumab, both TNF antagonists.
These drugs suppress the immune system broadly. For an adult, that tradeoff is often acceptable. For a child who will be on these medications through adolescence and potentially into adulthood, systemic immunosuppression carries compounding risks: increased susceptibility to serious infections, potential effects on growth and development, and long-term safety concerns that simply have not been studied over decades of pediatric use. Vedolizumab operates differently. As a humanized monoclonal antibody that selectively targets the α4β7 integrin, it blocks lymphocyte migration specifically to the gut mucosa. Inflammation is reduced where it matters — in the intestinal lining — without broadly dampening the immune response throughout the body. For a seven-year-old whose immune system is still maturing, or a teenager navigating school and social life, this distinction between gut-selective and systemic immunosuppression is not academic. It is the difference between a treatment that addresses the disease and one that creates a new set of vulnerabilities.
What the KEPLER Trial Results Actually Show — And Where They Fall Short
The headline number from KEPLER — 47.3 percent clinical remission at 54 weeks — requires context. The trial enrolled children and adolescents with moderately to severely active ulcerative colitis who had inadequate responses to conventional therapy, including steroids, immunomodulators, and in some cases TNF antagonists. All patients first received a 14-week open-label induction phase with intravenous vedolizumab. At the end of induction, 34.7 percent had already achieved clinical remission. Those who responded were then randomized into a 40-week double-blind maintenance phase comparing low-dose and high-dose regimens. By week 54, 47.3 percent of the randomized group was in remission, and 29 percent had sustained remission at both the week 14 and week 54 marks. These numbers are clinically meaningful, but they are not a cure. Roughly half of the patients who entered maintenance did not achieve remission at one year.
And the 29 percent sustained remission rate means that for every ten children who start vedolizumab induction, fewer than three will be in continuous remission a year later. This is not a failure of the drug — it reflects the stubborn reality of IBD, a chronic disease with no known cure where remission is the best achievable outcome. However, families should understand that vedolizumab is not a guarantee, and a substantial portion of children will need alternative or additional therapies. On the safety front, the results were reassuring. The adverse event profile was consistent with what has been observed in adults over more than a decade of use, with no new safety signals. The most common side effects occurring in ten percent or more of patients were upper respiratory infections at 30 percent, disease worsening at 17.5 percent, and fever at 12.5 percent. For a pediatric population, the absence of unexpected safety concerns is significant — though longer-term pediatric safety data will be essential as the drug moves toward regulatory approval. Results were presented at the 21st Congress of the European Crohn’s and Colitis Organisation in February 2026, and Takeda has announced plans to submit marketing applications in the United States, European Union, and other markets to extend approval to patients ages two through seventeen.
The Gut-Brain Connection — Why Dementia Researchers Should Pay Attention to Pediatric IBD
For readers following brain health and dementia research, the intersection of gut inflammation and neurological outcomes is not speculative — it is an active and growing area of investigation. The gut-brain axis, the bidirectional communication network linking the enteric nervous system with the central nervous system, means that chronic intestinal inflammation does not stay confined to the abdomen. Systemic inflammatory markers elevated in IBD, including C-reactive protein and various cytokines, have been associated with increased risk of cognitive decline and neurodegeneration in longitudinal studies of adult populations. What makes the pediatric angle particularly important is the developmental window. A child diagnosed with IBD at age five or ten who spends years in a state of chronic inflammation is experiencing that inflammation during critical periods of brain development.
The long-term neurological consequences of sustained pediatric gut inflammation are not yet well characterized, but the biological plausibility is strong. Vedolizumab’s gut-selective mechanism is relevant here precisely because it reduces intestinal inflammation without the systemic immunosuppressive effects that could independently affect brain health. A drug that quells gut inflammation while preserving normal immune surveillance elsewhere in the body, including the central nervous system, is theoretically more favorable for long-term neurological outcomes than one that suppresses immunity broadly. This is not to overstate the evidence — no clinical trial has directly measured vedolizumab’s effects on neurodevelopmental outcomes in children. But for a field that increasingly recognizes midlife inflammation as a modifiable risk factor for late-life dementia, the question of how we manage chronic inflammatory diseases in childhood has implications that extend well beyond gastroenterology.
How Vedolizumab Compares to Other Biologics in the Pediatric Pipeline
Vedolizumab is not the only drug being studied for pediatric IBD, and families navigating treatment decisions benefit from understanding the broader landscape. Risankizumab, an anti-IL-23 antibody, is currently in Phase 3 trials for pediatric Crohn’s disease in patients ages two to seventeen. Upadacitinib, marketed as Rinvoq, is a JAK inhibitor in Phase 3 trials for pediatric Crohn’s disease in patients ages two to eighteen. Tofacitinib, another JAK inhibitor, is being evaluated for pediatric ulcerative colitis. And ustekinumab, sold as Stelara, which targets both IL-12 and IL-23, is in Phase 3 pediatric trials for both Crohn’s disease and ulcerative colitis, though it remains approved only for adults. The key tradeoff among these options comes down to mechanism and risk profile. TNF antagonists like infliximab, the current workhorse in pediatric IBD, work well for many patients but carry risks of serious infections, reactivation of latent tuberculosis, and rare but concerning lymphoma risk — particularly hepatosplenic T-cell lymphoma in young males on combination therapy with thiopurines.
JAK inhibitors like upadacitinib offer the convenience of oral dosing but have raised safety signals in adult populations including increased cardiovascular events and malignancy risk, prompting FDA black box warnings. Whether those risks translate to pediatric populations remains uncertain, but they give clinicians and families pause. Vedolizumab’s gut-selective mechanism sidesteps many of these concerns. It does not suppress the immune system broadly enough to significantly elevate systemic infection risk, and its decade-plus track record in adults has not produced the alarming safety signals seen with some alternatives. The tradeoff is that its selectivity may limit its efficacy for patients with extraintestinal manifestations of IBD — joint inflammation, skin conditions, or eye involvement — where systemic immune modulation is actually needed. For a child whose IBD is primarily intestinal, vedolizumab is arguably the safest biologic option. For a child with significant disease outside the gut, a systemically active drug may be more appropriate despite the higher risk profile.
The Approval Gap — Why Pediatric Patients Wait Years for Drugs Adults Already Have
One of the most persistent and damaging patterns in pharmaceutical development is the delay between adult and pediatric drug approvals. Vedolizumab was approved for adults in 2014. If Takeda’s regulatory submissions succeed, pediatric approval could come in 2027 — thirteen years later. During that gap, pediatric gastroenterologists have been forced to use the drug off-label, relying on adult dosing data, clinical intuition, and small retrospective studies rather than the kind of rigorous evidence that the KEPLER trial now provides. This is not unique to vedolizumab. As researchers have documented, children with IBD have been systematically disadvantaged by drug approval policies that treat pediatric trials as an afterthought rather than a parallel priority. The reasons are partly economic — pediatric populations are smaller, trials are more complex and expensive to run, and the return on investment is lower.
They are partly regulatory — until relatively recent incentive programs, there was little compulsion for companies to conduct pediatric studies at all. And they are partly ethical — the bar for enrolling children in clinical trials is appropriately higher, requiring additional safeguards that slow recruitment. The consequence is that children bear the greatest risk with the least evidence. A thirteen-year-old receiving off-label vedolizumab is getting a drug whose pharmacokinetics, optimal dosing, and safety profile have never been formally established in someone their size and developmental stage. The KEPLER trial is a corrective, but it is one trial for one indication — ulcerative colitis. Pediatric Crohn’s disease data for vedolizumab remains limited. Families and clinicians should understand that even as the approval landscape improves, significant evidence gaps persist, and off-label use will remain common in pediatric gastroenterology for the foreseeable future.
The Rising Prevalence Problem — Why More Children Are Getting IBD
The numbers are difficult to ignore. Pediatric IBD prevalence in the United States increased 133 percent between 2007 and 2016, climbing from 33.0 to 77.0 per 100,000 children. As of the most recent CDC-funded data, Crohn’s disease affects approximately 71 per 100,000 children and ulcerative colitis 44 per 100,000. Compared to 2009 figures, Crohn’s prevalence rose roughly 22 percent and ulcerative colitis about 29 percent.
The highest rates are observed among White youth and in the Northeastern United States, though prevalence is increasing across demographic groups. The drivers of this increase remain incompletely understood, but leading hypotheses center on environmental and microbiome-related factors: changes in diet toward processed and ultra-processed foods, widespread early antibiotic exposure, reduced microbial diversity in increasingly sanitized environments, and possibly environmental pollutants that disrupt gut barrier function. Whatever the causes, the rising prevalence means that the population of children who need effective, well-studied treatments is growing. A drug like vedolizumab, with a favorable safety profile and now robust pediatric efficacy data, arrives at a moment when the need is both large and accelerating.
What Comes Next for Pediatric IBD Treatment
The next twelve to eighteen months will be pivotal. Takeda’s regulatory submissions for pediatric vedolizumab are expected across the United States, European Union, and other major markets. If approved for children ages two to seventeen with moderately to severely active ulcerative colitis, Entyvio would become one of the few biologics with a formal pediatric indication for IBD — a meaningful shift in a field where off-label prescribing has been the uncomfortable norm.
Beyond vedolizumab, the broader pipeline suggests that the era of pediatric IBD patients having only one or two biologic options may be ending. With risankizumab, upadacitinib, tofacitinib, and ustekinumab all in various stages of pediatric development, the next five years could bring a genuine expansion of treatment choices. The challenge will be ensuring that this expansion is accompanied by head-to-head comparative studies, long-term safety registries, and real-world effectiveness data — the tools clinicians need to match the right drug to the right child. For a disease that often begins in childhood and persists for a lifetime, getting the first biologic choice right matters enormously.
Conclusion
Vedolizumab’s KEPLER trial results represent the most significant advance in pediatric IBD treatment in years — not because the drug is new, but because rigorous Phase 3 evidence in children has been so conspicuously absent. A 47.3 percent remission rate at one year, achieved in patients who had already failed conventional therapies, combined with a safety profile consistent with over a decade of adult use and a gut-selective mechanism that avoids systemic immunosuppression, makes a compelling case for this drug as a frontline biologic option for children with ulcerative colitis. The absence of new safety signals in a pediatric population is particularly reassuring. For families navigating a child’s IBD diagnosis, the practical takeaway is that the treatment landscape is improving — but slowly.
Vedolizumab is not yet approved for pediatric use, and even when it is, it will not work for every child. The 29 percent sustained remission rate is honest about the drug’s limitations. What has changed is that pediatric patients and their clinicians are finally getting the kind of evidence they need to make informed treatment decisions, rather than extrapolating from adult data and hoping for the best. That shift — from guesswork to evidence — is the real revolution, and it is long overdue.
Frequently Asked Questions
Is vedolizumab currently FDA-approved for children?
No. As of early 2026, vedolizumab is FDA-approved only for adults with moderately to severely active ulcerative colitis and Crohn’s disease. However, following positive Phase 3 KEPLER trial results, Takeda plans to submit marketing applications to extend approval to children and adolescents ages two to seventeen. Some pediatric gastroenterologists currently prescribe it off-label based on adult data and clinical experience.
How does vedolizumab differ from infliximab and other TNF antagonists used in children?
Vedolizumab is gut-selective — it targets the α4β7 integrin to block immune cell migration specifically to the intestinal lining, reducing GI inflammation without suppressing the immune system throughout the body. TNF antagonists like infliximab work systemically, which can be more effective for IBD with extraintestinal manifestations but carries higher risks of serious infections and other systemic side effects, a particular concern in growing children.
What were the main results of the KEPLER trial?
In the Phase 3 KEPLER trial of pediatric patients ages two to seventeen with moderately to severely active ulcerative colitis, 34.7 percent achieved clinical remission after 14 weeks of induction therapy, and 47.3 percent of randomized patients achieved remission at 54 weeks. Sustained remission at both time points was observed in 29 percent. The safety profile was consistent with adult data, with no new safety signals identified.
How common is IBD in children?
Over 100,000 American youth under age 20 are living with IBD, with Crohn’s disease affecting approximately 71 per 100,000 children and ulcerative colitis affecting 44 per 100,000. Pediatric IBD prevalence increased 133 percent between 2007 and 2016, and rates continue to rise across demographic groups.
Are there other new drugs being studied for pediatric IBD?
Yes. Risankizumab, an anti-IL-23 antibody, is in Phase 3 trials for pediatric Crohn’s disease. Upadacitinib, a JAK inhibitor, is in Phase 3 for pediatric Crohn’s. Tofacitinib is being evaluated for pediatric ulcerative colitis. Ustekinumab is in Phase 3 trials for both pediatric Crohn’s and ulcerative colitis. If these trials succeed, pediatric patients could have meaningfully more treatment options within the next several years.
Does childhood IBD affect brain health or dementia risk later in life?
This is an active area of research. Chronic systemic inflammation, which is elevated in IBD, has been associated with increased risk of cognitive decline and neurodegeneration in adult studies. The long-term neurological consequences of sustained pediatric gut inflammation are not yet well established, but the biological plausibility of a connection through the gut-brain axis has prompted growing interest among researchers studying modifiable risk factors for dementia.
